Skip to main content
NCD 190.14 · version 3 · Laboratory NCD

NCD 190.14: Human Immunodeficiency Virus (HIV) Testing (Diagnosis)

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026); Lab NCD code lists: October 2026 (effective October 1, 2026). Next CMS release: weekly, every Thursday for the Medicare Coverage Database NCDs; January 1, 2027 (quarterly update) for the Lab NCD code lists.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 190.14

Benefit category
No Benefit Category
Effective date
12/08/2009
Implemented 07/06/2010
Transmittal
Transmittal 131
Versions published
3
Manual section
190
Pathology and Laboratory, NCD Manual (Pub. 100-03) chapter 1 part 3
Lab edit list
1,068 covered ICD-10
233 non-covered

TL;DR

NCD 190.14 sets Medicare's national policy for human immunodeficiency virus (hiv) testing (diagnosis) under the benefit category "No Benefit Category", effective 12/08/2009 and implemented 07/06/2010. Diagnostic testing to establish HIV infection may be indicated when there is a strong clinical suspicion supported by one or more of the following clinical findings: As a laboratory NCD it carries a national ICD-10 edit list: 1,068 diagnosis codes support medical necessity and 233 are denied, applied automatically by every Medicare contractor to 10 procedure codes.

Item or service described

Diagnosis of HIV infection is primarily made through the use of serologic assays. These assays take one of two forms: antibody detection assays and specific HIV antigen (p24) procedures. The antibody assays are usually enzyme immunoassays (EIA) which are used to confirm exposure of an individual's immune system to specific viral antigens. These assays may be formatted to detect HIV-1, HIV-2, or HIV-1 and 2 simultaneously and to detect both IgM and IgG. When the initial EIA test is repeatedly positive or indeterminant, an alternative test is used to confirm the specificity of the antibodies to individual viral components. The most commonly used method is the Western Blot.

The HIV-1 core antigen (p24) test detects circulating viral antigen which may be found prior to the development of antibodies and may also be present in later stages of illness in the form of recurrent or persistent antigenemia. Its prognostic utility in HIV infection has been diminished as a result of development of sensitive viral RNA assays, and its primary use today is as a routine screening tool in potential blood donors.

In several unique situations, serologic testing alone may not reliably establish an HIV infection. This may occur because the antibody response (particularly the IgG response detected by Western Blot) has not yet developed (that is, acute retroviral syndrome), or is persistently equivocal because of inherent viral antigen variability. It is also an issue in perinatal HIV infection due to transplacental passage of maternal HIV antibody. In these situations, laboratory evidence of HIV in blood by culture, antigen assays, or proviral DNA or viral RNA assays, is required to establish a definitive determination of HIV infection.

Indications and limitations of coverage

Indications

Diagnostic testing to establish HIV infection may be indicated when there is a strong clinical suspicion supported by one or more of the following clinical findings:

• The patient has a documented, otherwise unexplained, AIDS-defining or AIDS-associated opportunistic infection.

• The patient has another documented sexually transmitted disease which identifies significant risk of exposure to HIV and the potential for an early or subclinical infection.

• The patient has documented acute or chronic hepatitis B or C infection that identifies a significant risk of exposure to HIV and the potential for an early or subclinical infection.

• The patient has a documented AIDS-defining or AIDS-associated neoplasm.

• The patient has a documented AIDS-associated neurologic disorder or otherwise unexplained dementia.

• The patient has another documented AIDS-defining clinical condition, or a history of other severe, recurrent, or persistent conditions which suggest an underlying immune deficiency (for example, cutaneous or mucosal disorders).

• The patient has otherwise unexplained generalized signs and symptoms suggestive of a chronic process with an underlying immune deficiency (for example, fever, weight loss, malaise, fatigue, chronic diarrhea, failure to thrive, chronic cough, hemoptysis, shortness of breath, or lymphadenopathy).

• The patient has otherwise unexplained laboratory evidence of a chronic disease process with an underlying immune deficiency (for example, anemia, leukopenia, pancytopenia, lymphopenia, or low CD4+ lymphocyte count).

• The patient has signs and symptoms of acute retroviral syndrome with fever, malaise, lymphadenopathy, and skin rash.

• The patient has documented exposure to blood or body fluids known to be capable of transmitting HIV (for example, needle sticks and other significant blood exposures) and antiviral therapy is initiated or anticipated to be initiated.

• The patient is undergoing treatment for rape. (HIV testing is a part of the rape treatment protocol.)

Limitations

• HIV antibody testing in the United States is usually performed using HIV-1 or HIV-½ combination tests. HIV-2 testing is indicated if clinical circumstances suggest HIV-2 is likely (that is, compatible clinical findings and HIV-1 test negative). HIV-2 testing may also be indicated in areas of the country where there is greater prevalence of HIV-2 infections.

• The Western Blot test should be performed only after documentation that the initial EIA tests are repeatedly positive or equivocal on a single sample.

• The HIV antigen tests currently have no defined diagnostic usage.

• Direct viral RNA detection may be performed in those situations where serologic testing does not establish a diagnosis but strong clinical suspicion persists (for example, acute retroviral syndrome, nonspecific serologic evidence of HIV, or perinatal HIV infection).

• If initial serologic tests confirm an HIV infection, repeat testing is not indicated.

• If initial serologic tests are HIV EIA negative and there is no indication for confirmation of infection by viral RNA detection, the interval prior to retesting is 3-6 months.

• Testing for evidence of HIV infection using serologic methods may be medically appropriate in situations where there is a risk of exposure to HIV.

• The CPT Editorial Panel has issued a number of codes for infectious agent detection by direct antigen or nucleic acid probe techniques that have not yet been developed or are only being used on an investigational basis. Laboratory providers are advised to remain current on FDA-approval status for these tests.

Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).

Text reproduced from the CMS Medicare Coverage Database record for NCD 190.14 version 3. View the original on cms.gov.

Laboratory NCD code lists (October 2026)

Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list holds 1,068 covered and 233 non-covered ICD-10-CM codes; any code not on the list does not support medical necessity.

10 procedure codes are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.

Procedure codes subject to NCD 190.14
CodeCode set
86689CPT (descriptor licensed by AMA)
86701CPT (descriptor licensed by AMA)
86702CPT (descriptor licensed by AMA)
86703CPT (descriptor licensed by AMA)
87390CPT (descriptor licensed by AMA)
87391CPT (descriptor licensed by AMA)
87534CPT (descriptor licensed by AMA)
87535CPT (descriptor licensed by AMA)
87537CPT (descriptor licensed by AMA)
87538CPT (descriptor licensed by AMA)

What Medicare pays for these tests: 10 of the 10 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $8.89 to $35.09, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.

Clinical Laboratory Fee Schedule amounts for the codes NCD 190.14 edits, October 2026
CodeCLFS amountWith QWPricing
86689$19.35—national payment amount
86701$8.89$8.89national payment amount
86702$13.52—national payment amount
86703$13.71—national payment amount
87390$24.06—national payment amount
87391$21.90—national payment amount
87534$21.92—national payment amount
87535$35.09—national payment amount
87537$21.92—national payment amount
87538$35.09—national payment amount
Source: CMS Clinical Laboratory Fee Schedule 26CLABQ4. Every code range and the October changes are on the Clinical Laboratory Fee Schedule page.

The first 40 of 1,068 covered diagnosis codes, with FY2027 ICD-10-CM descriptions. A claim with any covered code on the line supports medical necessity under the national edit.

Covered ICD-10-CM codes for NCD 190.14 (sample)
ICD-10-CMDescriptionEffective
A02.1Salmonella sepsis2015-10-01
A07.2Cryptosporidiosis2015-10-01
A07.3Isosporiasis2015-10-01
A07.8Other specified protozoal intestinal diseases2015-10-01
A15.0Tuberculosis of lung2015-10-01
A15.4Tuberculosis of intrathoracic lymph nodes2015-10-01
A15.5Tuberculosis of larynx, trachea and bronchus2015-10-01
A15.6Tuberculous pleurisy2015-10-01
A15.7Primary respiratory tuberculosis2015-10-01
A15.8Other respiratory tuberculosis2015-10-01
A15.9Respiratory tuberculosis unspecified2015-10-01
A17.0Tuberculous meningitis2015-10-01
A17.1Meningeal tuberculoma2015-10-01
A17.81Tuberculoma of brain and spinal cord2015-10-01
A17.82Tuberculous meningoencephalitis2015-10-01
A17.83Tuberculous neuritis2015-10-01
A17.89Other tuberculosis of nervous system2015-10-01
A17.9Tuberculosis of nervous system, unspecified2015-10-01
A18.01Tuberculosis of spine2015-10-01
A18.02Tuberculous arthritis of other joints2015-10-01
A18.03Tuberculosis of other bones2015-10-01
A18.09Other musculoskeletal tuberculosis2015-10-01
A18.10Tuberculosis of genitourinary system, unspecified2015-10-01
A18.11Tuberculosis of kidney and ureter2015-10-01
A18.12Tuberculosis of bladder2015-10-01
A18.13Tuberculosis of other urinary organs2015-10-01
A18.14Tuberculosis of prostate2015-10-01
A18.15Tuberculosis of other male genital organs2015-10-01
A18.16Tuberculosis of cervix2015-10-01
A18.17Tuberculous female pelvic inflammatory disease2015-10-01
A18.18Tuberculosis of other female genital organs2015-10-01
A18.2Tuberculous peripheral lymphadenopathy2015-10-01
A18.31Tuberculous peritonitis2015-10-01
A18.32Tuberculous enteritis2015-10-01
A18.39Retroperitoneal tuberculosis2015-10-01
A18.4Tuberculosis of skin and subcutaneous tissue2015-10-01
A18.50Tuberculosis of eye, unspecified2015-10-01
A18.51Tuberculous episcleritis2015-10-01
A18.52Tuberculous keratitis2015-10-01
A18.53Tuberculous chorioretinitis2015-10-01

233 diagnosis codes deny automatically under this NCD; the first 20 are shown.

Non-covered ICD-10-CM codes for NCD 190.14 (sample)
ICD-10-CMDescription
R99Ill-defined and unknown cause of mortality
Z00.00Encounter for general adult medical examination without abnormal findings
Z00.01Encounter for general adult medical examination with abnormal findings
Z00.110Health examination for newborn under 8 days old
Z00.111Health examination for newborn 8 to 28 days old
Z00.121Encounter for routine child health examination with abnormal findings
Z00.129Encounter for routine child health examination without abnormal findings
Z00.5Encounter for examination of potential donor of organ and tissue
Z00.6Encounter for examination for normal comparison and control in clinical research program
Z00.70Encounter for examination for period of delayed growth in childhood without abnormal findings
Z00.71Encounter for examination for period of delayed growth in childhood with abnormal findings
Z00.8Encounter for other general examination
Z02.0Encounter for examination for admission to educational institution
Z02.1Encounter for pre-employment examination
Z02.2Encounter for examination for admission to residential institution
Z02.3Encounter for examination for recruitment to armed forces
Z02.4Encounter for examination for driving license
Z02.5Encounter for examination for participation in sport
Z02.6Encounter for examination for insurance purposes
Z02.71Encounter for disability determination

Changed in October 2026

The October 2026 lab NCD release changed this NCD's ICD-10-CM list: 5 codes added and 2 codes removed against January 2026. CMS marked 5 rows of the list as changed in this release. A removed code stops counting for the edit after its term date; where the FY2027 ICD-10-CM update deleted the code, the replacement codes listed below are the ones to report from October 1, 2026.

ICD-10-CM codes added to NCD 190.14 in October 2026
ICD-10-CMFY2027 descriptionResult
I42.00Dilated cardiomyopathy, unspecifiedcovered
I42.01Familial-genetic dilated cardiomyopathycovered
I42.09Other dilated cardiomyopathycovered
I42.81Arrhythmogenic cardiomyopathycovered
I42.89Other cardiomyopathies not elsewhere classifiedcovered
ICD-10-CM codes removed from NCD 190.14 in October 2026
ICD-10-CMDescriptionWasWhy
I42.0Dilated cardiomyopathycovereddeleted from ICD-10-CM; replaced by I42.00, I42.01, I42.09
I42.8Other cardiomyopathiescovereddeleted from ICD-10-CM; replaced by I42.81, I42.89

Codes on this NCD's list by release: October 2025: 1,294 · January 2026: 1,298 · October 2026: 1,301. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.

Local policies that build on this NCD

4 active Local Coverage Determinations cite NCD 190.14 among their related national policies. An LCD may not conflict with the national determination; read it for the contractor's documentation and coding detail in that jurisdiction.

  • MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (L39044) · Wisconsin Physicians Service Insurance Corporation
  • L38988 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing · Palmetto GBA
  • L39001 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing · Noridian Healthcare Solutions, LLC
  • L39038 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing · CGS Administrators, LLC

How MACs bill NCD 190.14

A National Coverage Determination states the policy; the Medicare Administrative Contractors publish the articles that turn it into claim edits. 4 current articles in the Medicare Coverage Database name NCD 190.14, 4 of them with a covered ICD-10-CM list, from 4 contractors. The lists can differ by contractor even though the NCD is national, because each MAC codes the policy for its own claims system; check the article of the contractor that processes the claim.

A58710: Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing

Billing and Coding, effective 2026-08-06 · Palmetto GBA (10111, 10112, 10211, 10212, 10311, 10312, 11201, 11202, 11301, 11302, 11401, 11402, 11501, 11502) · CMS record

851 covered ICD-10-CM codes in 11 groups; 137 procedure codes: 0068U, 0096U, 0109U, 0115U, 0140U, 0141U, 0142U, 0202U, 0223U, 0225U, 0301U, 0302U and 125 more. Local policy: L38988 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing. Check a diagnosis for 0068U.

First covered codes: A37.00 Whooping cough due to Bordetella pertussis without pneumonia; A37.01 Whooping cough due to Bordetella pertussis with pneumonia; A37.10 Whooping cough due to Bordetella parapertussis without pneumonia; A37.11 Whooping cough due to Bordetella parapertussis with pneumonia; A37.80 Whooping cough due to other Bordetella species without pneumonia; A37.81 Whooping cough due to other Bordetella species with pneumonia; …

A58720: Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing

Billing and Coding, effective 2026-08-06 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record

851 covered ICD-10-CM codes in 11 groups; 137 procedure codes: 0068U, 0096U, 0109U, 0115U, 0140U, 0141U, 0142U, 0202U, 0223U, 0225U, 0301U, 0302U and 125 more. Local policy: L39001 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing. Check a diagnosis for 0068U.

First covered codes: A37.00 Whooping cough due to Bordetella pertussis without pneumonia; A37.01 Whooping cough due to Bordetella pertussis with pneumonia; A37.10 Whooping cough due to Bordetella parapertussis without pneumonia; A37.11 Whooping cough due to Bordetella parapertussis with pneumonia; A37.80 Whooping cough due to other Bordetella species without pneumonia; A37.81 Whooping cough due to other Bordetella species with pneumonia; …

A58747: Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing

Billing and Coding, effective 2026-05-14 · CGS Administrators, LLC (15101, 15102, 15201, 15202) · CMS record

852 covered ICD-10-CM codes in 11 groups; 137 procedure codes: 0068U, 0096U, 0109U, 0115U, 0140U, 0141U, 0142U, 0202U, 0223U, 0225U, 0301U, 0302U and 125 more. Local policy: L39038 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing. Check a diagnosis for 0068U.

First covered codes: A37.00 Whooping cough due to Bordetella pertussis without pneumonia; A37.01 Whooping cough due to Bordetella pertussis with pneumonia; A37.10 Whooping cough due to Bordetella parapertussis without pneumonia; A37.11 Whooping cough due to Bordetella parapertussis with pneumonia; A37.80 Whooping cough due to other Bordetella species without pneumonia; A37.81 Whooping cough due to other Bordetella species with pneumonia; …

A58761: Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing

Billing and Coding, effective 2026-08-06 · Wisconsin Physicians Service Insurance Corporation (05101, 05102, 05201, 05202, 05301, 05302, 05401, 05402, 05901, 08101, 08102, 08201, 08202) · CMS record

851 covered ICD-10-CM codes in 11 groups; 137 procedure codes: 0068U, 0096U, 0109U, 0115U, 0140U, 0141U, 0142U, 0202U, 0223U, 0225U, 0301U, 0302U and 125 more. Local policy: L39044 MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing. Check a diagnosis for 0068U.

First covered codes: A37.00 Whooping cough due to Bordetella pertussis without pneumonia; A37.01 Whooping cough due to Bordetella pertussis with pneumonia; A37.10 Whooping cough due to Bordetella parapertussis without pneumonia; A37.11 Whooping cough due to Bordetella parapertussis with pneumonia; A37.80 Whooping cough due to other Bordetella species without pneumonia; A37.81 Whooping cough due to other Bordetella species with pneumonia; …

Revision history

12/2019 - Changes to the Laboratory National Coverage Determination (NCD) Edit Software for April 2020. This Change Request (CR) announces the changes that will be included in the April 2020 quarterly release of the edit module for clinical diagnostic laboratory services. This recurring update notification applies to chapter 16, section 120.2, publication 100-04. ( TN 4475 ) (CR11593)

02/2011 - Transmittal 118, dated March 23, 2010, is rescinded and replaced with Transmittal 131, dated February 23, 2011, to revise the descriptors of the 3 HIV screening codes to align with the descriptors in the official code files. All other material remains the same. ( TN 131 ) (CR6786)

03/2006 - Restore a portion of a sentence in limitation 7. Effective/Implementation date: 06/19/2006. ( TN 48 ) (CR4278)

07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)

07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 190.14

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 190.14

What does NCD 190.14 cover?

Diagnostic testing to establish HIV infection may be indicated when there is a strong clinical suspicion supported by one or more of the following clinical findings: The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 190.14 take effect?

The current version (3) is effective 12/08/2009, implemented 07/06/2010, published in transmittal 131. CMS lists 3 versions of this NCD.

Does a Local Coverage Determination override NCD 190.14?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Which diagnosis codes are covered under NCD 190.14?

The October 2026 laboratory NCD edit list contains 1,068 ICD-10-CM codes that support human immunodeficiency virus (hiv) testing (diagnosis) (for example A02.1 Salmonella sepsis; A07.2 Cryptosporidiosis; A07.3 Isosporiasis) and 233 codes that deny. The list applies to 86689, 86701, 86702, 86703, 87390, 87391 and others.

How often does the lab NCD code list for 190.14 change?

CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.

CMS guidance

Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.